Might be good dayJust a reminder on a crappy day that blue sky break out is ahead.
Valuation Points to $1.00/share
The combination of variables we could input on assumptions are infinitesimal in projections, however simply extrapolating conservatively off of contracts in hand, continuation of current growth penetration rates Y/Y, rate of conversions, the fact revenues are expected to conservatively hit an annualized rate of $6.8 million next year, and assuming a continuation of straight-line adoption (it actually appears that ADK.V is way early in the adoption curve and the curve is more likely to be parabolic or hyperbolic), we project the following minimums:
Straight-line adoption:
| Total Market: | $10B | $11B | $12B | $13B | $14B |
| Year-end Mar. 31: | 2017 | 2018 | 2019 | 2020 | 2021 |
| Share of market: | 0.035% | 0.063% | 0.115% | 0.23% | .28% |
| Revenue for ADK: | $3.5 M | $7 M | $18M | $30M | $40M |
| Net Profit : | $,7 M | $1.4M | $3.6M | $6.0M | $8.0M |
| Value Share Target Price (minimum): | $.20 | $.40 | $.60 | $1.00 | $1.33 |
“With DIAGNOS’ CARA screening we were able to know which patients are at risk, counsel them effectively with the aid of DIAGNOS’ reports, and were able to make a positive difference in the patients lives. ... We look forward to DIAGNOS expanding their services in the UAE, and hope to have the service available in Ajman soon ”
Source: United Arab Emirates Ministry of Health